BioSig Technologies (NASDAQ:BSGM - Free Report) had its target price hoisted by Ascendiant Capital Markets from $2.50 to $10.00 in a report issued on Friday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.
BioSig Technologies Trading Down 14.1%
BSGM stock traded down $1.03 during midday trading on Friday, reaching $6.30. 1,455,203 shares of the company's stock traded hands, compared to its average volume of 325,437. The company has a 50-day simple moving average of $2.46 and a two-hundred day simple moving average of $1.58. BioSig Technologies has a 1-year low of $0.20 and a 1-year high of $8.80.
BioSig Technologies (NASDAQ:BSGM - Get Free Report) last released its quarterly earnings results on Monday, May 19th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Analysts expect that BioSig Technologies will post -0.88 EPS for the current fiscal year.
Institutional Trading of BioSig Technologies
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSGM. Geode Capital Management LLC acquired a new stake in BioSig Technologies in the fourth quarter worth about $143,000. Legacy Investment Solutions LLC acquired a new stake in shares of BioSig Technologies in the 4th quarter valued at approximately $5,369,000. Integrity Wealth Advisors Inc. bought a new position in shares of BioSig Technologies in the fourth quarter valued at $61,000. Millennium Management LLC bought a new stake in BioSig Technologies in the fourth quarter valued at approximately $228,000. Finally, PFG Investments LLC raised its stake in BioSig Technologies by 43.5% in the first quarter. PFG Investments LLC now owns 158,286 shares of the company's stock valued at $95,000 after buying an additional 48,000 shares during the period. 7.16% of the stock is currently owned by institutional investors and hedge funds.
About BioSig Technologies
(
Get Free Report)
BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.
Featured Articles
Before you consider Biosig Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biosig Technologies wasn't on the list.
While Biosig Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
